Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

961.44 -19.89 (-2.03%)
Delayed Quote Updated: 3:48 PM EST, Nov 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
News headline image
What's Going On Pfizer's Subsidiary Biohaven Stock? ↗
Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an  
Via Benzinga
News headline image
Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29% ↗
The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases. 
Via Investor's Business Daily
News headline image
Why Immunovant Stock Is Bolting Higher Today ↗
The company may have best-in-class autoimmune disease therapy under its roof. 
Via The Motley Fool
News headline image
Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering ↗
Both companies are working on drugs that lower an antibody tied to numerous autoimmune conditions. 
Via Investor's Business Daily
News headline image
Immunovant Soars 73% — And Slugs Argenx — As Autoimmune Disease Battle Heats Up ↗
Immunovant is hoping to come up with the best drug in its class, lowering a key antibody tied to autoimmune diseases. 
Via Investor's Business Daily
News headline image
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target. 
Via MarketBeat
News headline image
The Latest Analyst Ratings for argenx ↗
 
Via Benzinga
News headline image
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
News headline image
This New S&P 500 Entrant Leads 5 Stocks Near Buy Points ↗
These stocks could lead if the market rallies. 
Via Investor's Business Daily
Topics Stocks
News headline image
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
News headline image
What 20 Analyst Ratings Have To Say About argenx ↗
 
Via Benzinga
News headline image
Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗
 
Via Benzinga
News headline image
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Is Argenx Stock a Buy Now? ↗
Good news keeps rolling in for the biotech. 
Via The Motley Fool
News headline image
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
News headline image
Top AI Stock ANET Leads 5 Stocks Near Buy Points In Tough Market ↗
Arista Networks and Dutch biotech Argenx lead this weekend's watch list. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023 ↗
 
Via Benzinga
News headline image
Earnings Outlook For argenx ↗
 
Via Benzinga
News headline image
argenx Unusual Options Activity ↗
 
Via Benzinga
News headline image
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
Argenx Stock Rides 'Megabuster' Drug Excitement To 40% Gain Before Earnings ↗
Argenx is up around 40% in 2023 after shares soared nearly 30% in a single day last week. 
Via Investor's Business Daily
News headline image
argenx announces closing of global offering
From argenx SE
Via GlobeNewswire
News headline image
Why Shares of Argenx Jumped This Week ↗
The company's lead therapy showed progress in treating an autoimmune disorder. 
Via The Motley Fool
News headline image
Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review ↗
But all the major indexes are at or near 15-month highs. 
Via Investor's Business Daily
News headline image
The Latest Analyst Ratings for argenx ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023 ↗
 
Via Benzinga
News headline image
Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade ↗
On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81. 
Via Investor's Business Daily
News headline image
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
From argenx SE
Via GlobeNewswire
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS